Real-life switching strategies with second-generation antipsychotics.
Correll
Christoph U
CU
The Zucker Hillside Hospital, 75-59 263rd Street, Glen Oaks, NY 11004, USA. correll@lij.edu
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004351:Drug Resistance; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy; D000069348:Quetiapine Fumarate; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D015983:Selection Bias; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D000077152:Olanzapine